US20040062800A1 - Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles - Google Patents
Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles Download PDFInfo
- Publication number
- US20040062800A1 US20040062800A1 US10/451,271 US45127103A US2004062800A1 US 20040062800 A1 US20040062800 A1 US 20040062800A1 US 45127103 A US45127103 A US 45127103A US 2004062800 A1 US2004062800 A1 US 2004062800A1
- Authority
- US
- United States
- Prior art keywords
- composition
- agent
- dependent
- cellulose
- anagrelide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- This invention relates to pharmaceutical compositions. More particularly, this invention relates to pharmaceutical compositions having a pH-independent or a minimized pH-dependent dissolution profile.
- such composition includes at least one pharmaceutically active agent that has a pH dependent solubility profile, at least one non-pH-dependent sustained release agent, and at least one pH-dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5.
- the active agent(s) has (have) a solubility profile wherein the active agent(s) is (are) more soluble in an acidic medium than in a basic medium.
- Compressed matrix tablets containing a basic drug often give a faster dissolution profile in simulated gastric fluid, having a pH about 1.0, than in simulated intestinal fluid (pH 6.8 to 7.4).
- a pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH-dependent agent that increases the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5, such as at least one organic acid that maintains an acidic micro-environment in the tablet.
- Pharmaceutically active agents which are pH dependent and which may be included in the composition include, but are not limited to, weakly basic drugs and their salts that have higher solubilities at lower pH levels.
- Such drugs include, but are not limited to, guanfacine hydrochloride, guanadrel sulfate, reserpine, anagrelide hydrochloride, propanolol, metoprolol, atenolol, timolol, erthyrthromycin, clonidine, chlorpheniramine, bromopheniramine, diltiazen, and scopolamine.
- the pharmaceutically active agent is present in the composition in an amount of from about 0.1 wt, % to about 70 wt. %, preferably from about 1 wt. % to about 40 wt %.
- the at least one pharmaceutically active agent is guanfacine hydrochloride.
- the at least one pharmaceutically active agent is anagrelide hydrocholoride. It is to be understood, however, that the scope of the present invention is not to be limited to any particular pharmaceutically active agent.
- Non-pH-dependent sustained release agents which may be included in the composition include, but are not limited to, ethylcellulose, cellulose acetate, vinyl acetatelvinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
- the at least one non-pH-dependent sustained release agent is present in the composition in an amount of from about 5 wt. % to about 50 wt. %, preferably from about 10 wt. % to about 30 wt. %. It is to be understood, however, that the scope of the present invention is not to be limited to any particular non-pH-dependent sustained release agents.
- pH-dependent agents that increase the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5 include, but are not limited to, polymers that swell at a pH in excess of 5.5, and enteric agents, and/or agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5, by maintaining an acidic microenvironment in the tablet, e.g., an organic acid.
- the at least one pH-dependent agent is present in the composition in an amount of from about 0.5 wt. % to about 40 wt. %, preferably from about 1 wt. % to about 20 wt. %.
- Polymers that swell at a pH in excess of 5.5 include, but are not limited to, acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.
- Enteric agents include, but are not limited to, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid coplymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
- Agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5 include, but are not limited to, organic acids.
- organic acids maintain an acidic microenvironment in the tablet, and include, but are not limited to, citric acid, fumaric acid, tartaric acid, adipic acid, glucono delta-lactone, and malic acid.
- composition of the present invention may further include other materials such as bulking agents, disintegrating agents, anti-adherants and glidants, lubricants, and binding agents.
- Bulking agents include, but are not limited to, microcrystalline cellulose (eg., Avicel®, FMC Corp., Emcocel®, Mendell Inc.), mannitol, xylitol, dicalcium phosphate (eg. Emcompress, Mendell Inc.) calcium sulfate (eg.
- the bulking agent may be present in the composition in an amount of from about 5 wt. % to about 90 wt. %, preferably from about 10 wt. % to about 50 wt. %.
- Disintegrating agents which may be included in the composition include, but are not limited to, microcrystalline cellulose, starches, crospovidone (eg. Polyplasdone XL, International Specialty Products.), sodium starch glycolate (Explotab, Mendell Inc.), and crosscarmellose sodium (eg., Ac-Di-Sol, FMC Corp.).
- the disintegrating agent may be present in the composition in an amount of from about 0.5 wt. % to about 30 wt %, preferably from about 1 wt. % to about 15 wt. %.
- Antiadherants and glidants which may be employed in the composition include, but are not limited to, talc, corn starch, silicon dioxide, sodium lauryl sulfate, and metallic stearates.
- the antiadherant or glidant may be present in the composition in an amount of from about 0.2 wt. % to about 15 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
- Lubricants which may be employed in the composition include, but are not limited to, magnesium stearate, calcium stearate, sodium stearate, stearic acid, sodium stearyl fumarate, hydrogenated cotton seed oil (sterotex), talc, and waxes, including but not limited to, beeswax, carnuba wax, cetyl alcohol, glyceryl stearate, glyceryl palmitate, glyceryl behenate, hydrogenated vegetable oils, and stearyl alcohol.
- the lubricant may be present in an amount of from about 0.2 wt. % to about 20 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
- Binding agents which may be employed include, but are not limited to, polyvinyl pyrrollidone, starch, methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sucrose solution, dextrose solution, acacia, tragacanth and locust bean gum.
- the binding agent may be present in the composition in an amount of from about 0.2 wt. % to about 10 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
- compositions of the present invention may be made by a direct compression method, or by a wet granulation method.
- the direct compression method the at least one pharmaceutically active agent and other ingredients are sieved through a stainless steel screen, such as a 40 mesh steel screen.
- the sieved materials then are charged to a suitable blender, and blended for 10 minutes with an intensifier bar on for 3 minutes.
- the blend then is compressed into tablets on a rotary press using appropriate tooling.
- the compressed tablets may be coated, if desired.
- the at least one pharmaceutically active agent and other ingredients are granulated with a granulating fluid (e.g., isopropyl alcohol, ethyl alcohol, and water) in a planetary mixer, high shear mixer, or fluidized bed granulator. Binding agents may be contained in the granulating fluid, or may be in the dry mix.
- the wet granules are dried in an oven or fluidized bed dryer, and then sieved through a suitable screen to obtain free flowing granules.
- the resulting granules were blended with a suitable lubricant and glidant, and the lubricated granules are compressed into tablets on a rotary press using appropriate tooling. If desired, a coating can be applied onto the compressed tablets.
- the composition may be employed in treating an attention deficit disorder, or attention deficit with hyperactivity disorder.
- the composition including guanfacine hydrochloride is administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat the disorders mentioned hereinabove.
- compositions of the present invention may be employed to treat a variety of diseases or disorders.
- guanfacine hydrochloride When guanfacine hydrochloride is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of guanfacine hydrochloride, or a reduction in the likelihood of side effects associated with the administration of guanfacine hydrochloride.
- a pharmaceutical composition comprising guafancine as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with guafancine.
- the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations.
- the side effects are chosen from Headache or Asthenia.
- the composition may be employed in treating a variety of blood disorders, including, but not limited to, myeloproliferative blood disorders or MBDs, such as, for example, essential thrombocythemia, or ET, chronic myelogenous leukemia, or CML, polycythemia vera, or PV, and agnogenic myeloid metaplasia, or AMM.
- MBDs myeloproliferative blood disorders
- the composition including anagrelide may be administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat such disorders.
- the active agent anagrelide may be administered to a patient in an amount of from about 0.01 mg to 15 mg, preferably from about 0.1 mg to about 10 mg, more preferably from about 0.1 mg to about 5 mg and most preferably from about 0.5 mg to about 2 mg.
- anagrelide may be administered to a patient in an amount of 0.5 mg four times a day, or 1 mg twice a day, for at least one week.
- anagrelide is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of anagrelide, or a reduction of the likelihood of side effects associated with the administration of anagrelide.
- composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.
- the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations.
- the side effects are chosen from Headache or Asthenia.
- Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression described hereinabove.
- guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen.
- the sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes.
- the blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling
- a Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP23. The dissolution in 0.1N hydrochloric acid (pH 1.2) or pH 6.8 phosphate buffer was tested using the paddle method (USP Apparatus II), employing 500 ml of dissolution medium at a temperature of 37° C. and an agitation rate of 50 rpm. Samples at specific time points were removed and filtered through a 35 ⁇ m filter. The filtered samples were kept in screw cap glass test tubes until analysis. An HPLC system comprised of an autosampler and a pump and a UV detector was used for sample analysis. 50 ⁇ l of the dissolution samples were injected directly on the HPLC C18 column using a mixture of acetonitrile and acetate buffer (20:80) as the mobile phase.
- compositions of the present invention have improved dissolution profiles when compared with the control compositions.
- Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression method described hereinabove.
- guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen.
- the sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes.
- the blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling
- the solubility of anagrelide HCl in aqueous solutions in the pH range of 1 to 11.4 at 25° C. was determined.
- the solubility-pH profile of anagrelide HCl is shown in FIG. 1. Below pH 3, the solubility increased as the pH decreased which is consistent with formation of a more soluble protonated form. At pH 0.96 the solubility was 236 mcg/mL. Above pH 4, the solubility was independent of pH and remained constant (ca. 1.2 mcg/mL) up to pH 8. Above pH 8, the solubility increased with increasing pH which is due to the ionization of the quinazoline moiety. The solubility at pH 11.4 was 992 mcg/mL.
- Formulations I through IV were formulated according to the procedure described in Example 1, except that anagrelide HCl has been substituted for guanfacine HCl.
- a Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP 23. The dissolution in 0.1N hydrochloric acid (pH 1.1) with 0.1% Tween 80 or pH 6.8 phosphate buffer with 0.1% Tween 80 was tested using the paddle method (USP Apparatus II), employing 900 ml of dissolution medium at a temperature of 37° C., and an agitation rate of 100 rpm. Samples at specific time points were removed and filtered through a 70 ⁇ m filter. The filtered samples were kept in screw cap glass test tubes until analysis.
- Formulations V, VI, and VII which are modifications of Formulation IV of Example 2, include the following components as shown in Table 6 below.
- Table 6 Formulation V
- Formulation VI Component mg/tablet % mg/tablet % mg/tablet % mg/tablet %
- Anagrelide HCl Monohydrate* 0.63 0.315 1.26 0.630 1.88 0.940 Polyethylene Oxide, 60 Mesh
- Dibasic Calcium Phosphate Anhydrous
- USP Flujicalin SG
- Cellulose (Prosolv HD 90) USP Methacrylic Acid Copolymer
- Glyceryl Behenate NF 17.56 8.780 17.56 8.780 17.
- Formulations V, VI, and VII were prepared and processed into tablets according to the following procedure:
- step 8 Pass the blend from step 8 through a 30-mesh screen using a Comil at the low speed setting and collect it in a polyethylene bag.
- Formulations 1, 2, and 3 were prepared, which had the following components in the following amounts, as shown in Table 7 below.
- TABLE 7 Amount, wt % Formulation Formulation Formulation Component 1 2 3 Anagrelide HCl, Monohydrate 0.61 0.61 0.61 Polyethylene Oxide 15.00 — 25.00 (Polyox TM WSR 301) Polyethylene Oxide, 60 Mesh, — 20.00 — NF (Polyox TM WSR N80) Dibasic Calcium Phosphate, 30.61 20.61 30.61
- the purpose of this example was to assess the bioavailability of three anagrelide HCl extended release tablet formulationsFormulation 1Formulation 2Formulation 3, compared to an immediate release anagrelide HCl formulation (Agrylin®, Lot No. RPA 0002A), following a 1 mg dose, and to determine the safety and tolerability of the extended release formulations in healthy volunteers.
- T max maximum concentration
Abstract
A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
Description
- This invention relates to pharmaceutical compositions. More particularly, this invention relates to pharmaceutical compositions having a pH-independent or a minimized pH-dependent dissolution profile. In particular, such composition includes at least one pharmaceutically active agent that has a pH dependent solubility profile, at least one non-pH-dependent sustained release agent, and at least one pH-dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. The active agent(s) has (have) a solubility profile wherein the active agent(s) is (are) more soluble in an acidic medium than in a basic medium.
- The rate at which a drug goes into solution when it is dissolved in a medium is proportional to the solubility of the drug in the medium. Many drugs have different solubilities at different pHs. These pH-dependent solubility differences lead to pH-dependent dissolution profiles. In general, pH-dependent dissolution is an undesirable product characteristic.
- Compressed matrix tablets containing a basic drug often give a faster dissolution profile in simulated gastric fluid, having a pH about 1.0, than in simulated intestinal fluid (pH 6.8 to 7.4).
- It is an object of the present invention to provide a pharmaceutical composition with a minimized pH dependent or a pH-independent dissolution profile.
- In accordance with an aspect of the present invention, there is provided a pharmaceutical composition. The composition comprises at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH-dependent agent that increases the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5, such as at least one organic acid that maintains an acidic micro-environment in the tablet.
- Pharmaceutically active agents which are pH dependent and which may be included in the composition include, but are not limited to, weakly basic drugs and their salts that have higher solubilities at lower pH levels. Such drugs include, but are not limited to, guanfacine hydrochloride, guanadrel sulfate, reserpine, anagrelide hydrochloride, propanolol, metoprolol, atenolol, timolol, erthyrthromycin, clonidine, chlorpheniramine, bromopheniramine, diltiazen, and scopolamine. In general, the pharmaceutically active agent is present in the composition in an amount of from about 0.1 wt, % to about 70 wt. %, preferably from about 1 wt. % to about 40 wt %. In one embodiment, the at least one pharmaceutically active agent is guanfacine hydrochloride. In another embodiment, the at least one pharmaceutically active agent is anagrelide hydrocholoride. It is to be understood, however, that the scope of the present invention is not to be limited to any particular pharmaceutically active agent.
- Non-pH-dependent sustained release agents which may be included in the composition include, but are not limited to, ethylcellulose, cellulose acetate, vinyl acetatelvinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol. In general, the at least one non-pH-dependent sustained release agent is present in the composition in an amount of from about 5 wt. % to about 50 wt. %, preferably from about 10 wt. % to about 30 wt. %. It is to be understood, however, that the scope of the present invention is not to be limited to any particular non-pH-dependent sustained release agents.
- pH-dependent agents that increase the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5 include, but are not limited to, polymers that swell at a pH in excess of 5.5, and enteric agents, and/or agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5, by maintaining an acidic microenvironment in the tablet, e.g., an organic acid. The at least one pH-dependent agent is present in the composition in an amount of from about 0.5 wt. % to about 40 wt. %, preferably from about 1 wt. % to about 20 wt. %.
- Polymers that swell at a pH in excess of 5.5 include, but are not limited to, acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.
- Enteric agents include, but are not limited to, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid coplymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
- Agents that increase the solubility of the at least one pharmaceutically active agent at a pH greater than 5.5 include, but are not limited to, organic acids. Such organic acids maintain an acidic microenvironment in the tablet, and include, but are not limited to, citric acid, fumaric acid, tartaric acid, adipic acid, glucono delta-lactone, and malic acid.
- The composition of the present invention may further include other materials such as bulking agents, disintegrating agents, anti-adherants and glidants, lubricants, and binding agents.
- Bulking agents include, but are not limited to, microcrystalline cellulose (eg., Avicel®, FMC Corp., Emcocel®, Mendell Inc.), mannitol, xylitol, dicalcium phosphate (eg. Emcompress, Mendell Inc.) calcium sulfate (eg. Compactrol, Mendell Inc.) starches, lactose, sucrose (Dipac, Amstar, and Nutab, Ingredient Technology), dextrose (Emdex, Mendell, Inc.), sorbitol, cellulose powder (Elcema, Degussa, and Solka Floc, Mendell, Inc.) The bulking agent may be present in the composition in an amount of from about 5 wt. % to about 90 wt. %, preferably from about 10 wt. % to about 50 wt. %.
- Disintegrating agents which may be included in the composition include, but are not limited to, microcrystalline cellulose, starches, crospovidone (eg. Polyplasdone XL, International Specialty Products.), sodium starch glycolate (Explotab, Mendell Inc.), and crosscarmellose sodium (eg., Ac-Di-Sol, FMC Corp.). The disintegrating agent may be present in the composition in an amount of from about 0.5 wt. % to about 30 wt %, preferably from about 1 wt. % to about 15 wt. %.
- Antiadherants and glidants which may be employed in the composition include, but are not limited to, talc, corn starch, silicon dioxide, sodium lauryl sulfate, and metallic stearates. The antiadherant or glidant may be present in the composition in an amount of from about 0.2 wt. % to about 15 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
- Lubricants which may be employed in the composition include, but are not limited to, magnesium stearate, calcium stearate, sodium stearate, stearic acid, sodium stearyl fumarate, hydrogenated cotton seed oil (sterotex), talc, and waxes, including but not limited to, beeswax, carnuba wax, cetyl alcohol, glyceryl stearate, glyceryl palmitate, glyceryl behenate, hydrogenated vegetable oils, and stearyl alcohol. The lubricant may be present in an amount of from about 0.2 wt. % to about 20 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
- Binding agents which may be employed include, but are not limited to, polyvinyl pyrrollidone, starch, methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sucrose solution, dextrose solution, acacia, tragacanth and locust bean gum. The binding agent may be present in the composition in an amount of from about 0.2 wt. % to about 10 wt. %, preferably from about 0.5 wt. % to about 5 wt. %.
- The compositions of the present invention may be made by a direct compression method, or by a wet granulation method. In the direct compression method, the at least one pharmaceutically active agent and other ingredients are sieved through a stainless steel screen, such as a 40 mesh steel screen. The sieved materials then are charged to a suitable blender, and blended for 10 minutes with an intensifier bar on for 3 minutes. The blend then is compressed into tablets on a rotary press using appropriate tooling. The compressed tablets may be coated, if desired.
- In the wet granulation method, the at least one pharmaceutically active agent and other ingredients are granulated with a granulating fluid (e.g., isopropyl alcohol, ethyl alcohol, and water) in a planetary mixer, high shear mixer, or fluidized bed granulator. Binding agents may be contained in the granulating fluid, or may be in the dry mix. The wet granules are dried in an oven or fluidized bed dryer, and then sieved through a suitable screen to obtain free flowing granules. The resulting granules were blended with a suitable lubricant and glidant, and the lubricated granules are compressed into tablets on a rotary press using appropriate tooling. If desired, a coating can be applied onto the compressed tablets.
- When the pharmaceutically active agent is guanfacine hydrochloride, the composition may be employed in treating an attention deficit disorder, or attention deficit with hyperactivity disorder. The composition including guanfacine hydrochloride is administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat the disorders mentioned hereinabove.
- The compositions of the present invention may be employed to treat a variety of diseases or disorders.
- When guanfacine hydrochloride is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of guanfacine hydrochloride, or a reduction in the likelihood of side effects associated with the administration of guanfacine hydrochloride.
- In accordance with a further aspect of the present invention there is provided a pharmaceutical composition comprising guafancine as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with guafancine.
- In one embodiment the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations.
- In a further embodiment the side effects are chosen from Headache or Asthenia.
- When the pharmaceutically active agent is anagrelide, the composition may be employed in treating a variety of blood disorders, including, but not limited to, myeloproliferative blood disorders or MBDs, such as, for example, essential thrombocythemia, or ET, chronic myelogenous leukemia, or CML, polycythemia vera, or PV, and agnogenic myeloid metaplasia, or AMM. The composition including anagrelide may be administered to an animal, such as a mammal, including human and non-human primates, in an amount effective to treat such disorders.
- The active agent anagrelide may be administered to a patient in an amount of from about 0.01 mg to 15 mg, preferably from about 0.1 mg to about 10 mg, more preferably from about 0.1 mg to about 5 mg and most preferably from about 0.5 mg to about 2 mg. In one treatment regimen, anagrelide may be administered to a patient in an amount of 0.5 mg four times a day, or 1 mg twice a day, for at least one week. When anagrelide is administered as part of a composition in accordance with the present invention, there is a reduction in the number of side effects associated with the administration of anagrelide, or a reduction of the likelihood of side effects associated with the administration of anagrelide.
- In accordance with a further aspect of the present invention there is provided a pharmaceutical composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.
- In one embodiment the side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Infect, Vomit, or Palpitations.
- In a further embodiment the side effects are chosen from Headache or Asthenia.
- The invention now will be described with respect to the following examples; however, the scope of the present invention is not intended to be limited thereby.
- Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression described hereinabove. In accordance with such method, guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen. The sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes. The blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling
- The formulations are given in Table 1 below
TABLE 1 PD0052-22A PD0052-25B PD0052-28B PD0052-32B PD0052-32D PD0052- 39A Ingredient 1* 2** 1 2 1 2 1 2 1 2 1 2 Guanfacine 0.57 1.14 0.57 1.14 0.57 1.14 0.57 1.14 0.57 1.14 0.57 1.14 HCl Lactose 37.43 74.86 — — — — 45.00 90.00 65.00 130.00 — — — — ProSolv 20.00 40.00 — — 30.00 60.00 — — — — 29.82 59.64 Polyox WSR 40.00 80.00 40.00 80.00 — — 40.00 80.00 10.00 20.00 Ethocel FP — — — — 40.00 80.00 — — — — 39.82 79.64 Cellulose — — 50.00 100.00 — — — — — — — — acetate Sodium — — — — 20.00 40.00 — — — — — — alginate Carrageenan — — — — — — — — — — 19.91 39.82 Carbopol — — — — — — — — 10.00 20.00 — — 974P Fumaric acid — — — — — — 5.00 10.00 — — — — Eudragit — — — — — — — — 5.00 10.00 — — L100-55 EDTA — — — — — — — — — — 0.50 1.00 Compritol — — 9.43 18.86 9.43 18.63 9.43 18.63 9.43 18.63 9.37 18.74 Stearic acid 2.00 4.00 — — — — — — — — — — - The dissolution data was determined as follows:
- A Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP23. The dissolution in 0.1N hydrochloric acid (pH 1.2) or pH 6.8 phosphate buffer was tested using the paddle method (USP Apparatus II), employing 500 ml of dissolution medium at a temperature of 37° C. and an agitation rate of 50 rpm. Samples at specific time points were removed and filtered through a 35 μm filter. The filtered samples were kept in screw cap glass test tubes until analysis. An HPLC system comprised of an autosampler and a pump and a UV detector was used for sample analysis. 50 μl of the dissolution samples were injected directly on the HPLC C18 column using a mixture of acetonitrile and acetate buffer (20:80) as the mobile phase.
- The dissolution data are given in Table 2 below.
TABLE 2 Dissolution Data for Guanfacine Sustained Release Tablets Time PD0052-22A PD0052-25B PD0052-28B PD0052-32B PD0052-32D PD0052-39A (hour) 1* 2** 1 2 1 2 1 2 1 2 1 2 0.5 14.0 ± 0.6 7.0 ± 1.2 13.0 ± 1.5 5.0 ± 0.6 8.4 ± 2.1 10.0 ± 0.6 19.0 ± 1.2 12.0 ± 0.0 31.0 ± 1.2 11.0 ± 1.0 14.0 ± 0.6 10.0 ± 1.0 1.0 24.0 ± 1.0 12.0 ± 1.0 27.0 ± 2.0 7.0 ± 1.0 41.0 ± 1.7 20.0 ± 1.0 31.0 ± 2.6 20.0 ± 0.6 48.0 ± 1.2 19.0 ± 0.6 25.0 ± 1.0 18.0 ± 2.0 2.0 44.0 ± 0.6 19.0 ± 1.5 48.0 ± 2.5 11.0 ± 0.6 64.0 ± 2.5 36.0 ± 2.5 50.0 ± 4.2 35.0 ± 0.6 80.0 ± 5.6 31.0 ± 1.2 42.0 ± 1.0 31.0 ± 4.0 3.0 59.0 ± 0.6 26.0 ± 1.5 63.0 ± 1.7 14.0 ± 0.6 77.0 ± 2.6 49.0 ± 3.6 65.0 ± 6.1 49.0 ± 1.0 96.0 ± 5.0 46.0 ± 0.6 56.0 ± 2.6 46.0 ± 4.4 4.0 71.0 ± 6.0 31.0 ± 2.9 74.0 ± 1.5 16.0 ± 0.6 86.0 ± 3.2 59.0 ± 3.2 77.0 ± 5.5 61.0 ± 1.0 104 ± 3.5 56.0 ± 0.6 69.0 ± 3.0 56.0 ± 5.8 6.0 90.0 ± 2.0 39.0 ± 2.5 86.0 ± 1.7 19.0 ± 0.0 97.0 ± 3.5 71.0 ± 5.0 99.0 ± 4.4 87.0 ± 2.5 111 ± 4.0 74.0 ± 1.2 90.0 ± 2.6 72.0 ± 6.2 8.0 99.0 ± 1.7 46.0 ± 2.5 93.0 ± 2.1 21.0 ± 1.0 108 ± 3.8 80.0 ± 5.5 102 ± 1.2 97.0 ± 1.5 112 ± 4.0 89.0 ± 2.3 102 ± 2.3 83.0 ± 6.4 12.00 105.0 ± 61.0 ± 4.7 100.0 ± 25.0 ± 1.0 113 ± 3.6 91.0 ± 6.0 103 ± 2.3 98.0 ± 1.0 113 ± 3.8 107 ± 2.9 112 ± 0.6 96.0 ± 1.5 1.2 4.2 - The above results show that the compositions of the present invention have improved dissolution profiles when compared with the control compositions.
- Formulations in accordance with the present invention, as well as control formulations, were prepared according to the direct compression method described hereinabove. In accordance with such method, guanfacine HCl and other ingredients were sieved through a 40 mesh steel screen. The sieved materials then were charged into a Blendmaster blender (Patterson-Kelley Co.), and blended for 10 minutes with an intensifier bar on for 3 minutes. The blends then are compressed into tablets on a rotary tablet press (Stokes-Merrill Corp., Model 512) using appropriate tooling
- The formulations are given in Table 3 below.
TABLE 3 Weight Percentage of Components in Guanfacine MR Tablets, 1 mg, Batch Numbers 2015.00.001, 2016.00.001 and 2018.00.001 2015.00.001 2016.00.001 2018.00.001 Component (%) (%) (%) Guanfacine HCl, USP 0.57 0.57 0.57 Hydroxypropryl 10.00 15.00 5.00 Methylcellulose (Methocel K4M Premium CR), USP/NF Methacrylic Acid Copolymer 25.00 — — (Eudragit L 100-55), USP/NF Ammonio Methacrylate — 25.00 22.50 Copolymer (Eudragit RSPO), USP/NF Silicified Microcrystalline 25.00 20.00 34.43 Cellulose (Prosolv HD 90) Lactose Monohydrate 24.43 24.43 20.00 Povidone Crospovidone Granulated Blend (Ludipress) Fumaric Acid, USP/NF 5.00 10.00 5.00 Glyceryl Behenate (Compritol 10.00 5.00 12.50 888 ATO), USP/NF Total 100.00 100.00 100.00 - The solubility of anagrelide HCl in aqueous solutions in the pH range of 1 to 11.4 at 25° C. was determined. The solubility-pH profile of anagrelide HCl is shown in FIG. 1. Below
pH 3, the solubility increased as the pH decreased which is consistent with formation of a more soluble protonated form. At pH 0.96 the solubility was 236 mcg/mL. AbovepH 4, the solubility was independent of pH and remained constant (ca. 1.2 mcg/mL) up topH 8. AbovepH 8, the solubility increased with increasing pH which is due to the ionization of the quinazoline moiety. The solubility at pH 11.4 was 992 mcg/mL. - Formulations I through IV were formulated according to the procedure described in Example 1, except that anagrelide HCl has been substituted for guanfacine HCl.
- The formulations are given in Table 4 below.
TABLE 4 Formulation I Formulation II Formulation III Formulation IV Ingredients mg/Tablet % mg/Tablet % mg/Tablet % mg/Tablet % Anagrelide HCl 2.44 1.22 2.44 1.22 2.44 1.22 2.44 1.22 (2.0 base) (2.0 base) (2.0 base) (2.0 base) Polyox WSR 301 30.00 15.00 50.00 25.00 Prosolv HD 90 60.00 30.00 60.00 30.00 66.00 33.00 80.00 40.00 Fujicalin SG* 60.00 30.00 30.00 15.00 60.00 30.00 40.00 20.00 Eudragit L 100-55 20.00 10.00 30.00 15.00 24.00 12.00 20.00 10.00 Ethocel Std. 30.00 15.00 100 FP Fumaric Acid 10.00 5.00 10.00 5.00 Compritol 17.56 8.78 17.56 8.78 17.56 8.78 17.56 8.78 888 ATO Polyox WSR N80 40.00 20.00 Formulation # PD0073-55A PD0073-57A PD0073-64A PD0073-78A Total 200.00 100.00 200.00 100.00 200.00 100.00 200.00 100.00 - A Vankel dissolution tester (VanKel Industries, Edison, N.J.) was used for all dissolution studies. The apparatus was calibrated according to USP 23. The dissolution in 0.1N hydrochloric acid (pH 1.1) with 0.1% Tween 80 or pH 6.8 phosphate buffer with 0.1% Tween 80 was tested using the paddle method (USP Apparatus II), employing 900 ml of dissolution medium at a temperature of 37° C., and an agitation rate of 100 rpm. Samples at specific time points were removed and filtered through a 70 μm filter. The filtered samples were kept in screw cap glass test tubes until analysis. An HPLC system composed of an autosampler and a pump and a UV detector was used for sample analysis. 20 μl of the dissolution samples were injected directly on the HPLC C18 column using a mixture of acetonitrile and ammonium acetate buffer (36:64) as the mobile phase.
- The dissolution data are given in Table 5 below.
TABLE 5 Dissolution Data for Anagrelide Sustained Release Tablets PD0073-55A PD0073-57A PD0073-64A PD0073-78A Time(hour) 1* 2** 1 2 1 2 1 2 0.5 N/A 4.0 ± 0.6 6.0 ± 0.0 2.0 ± 0.0 27.0 ± 2.1 5.0 ± 1.0 16.0 ± 0.6 12.0 ± 1.2 1.0 13.0 ± 0.6 6.0 ± 0.0 9.0 ± 0.6 3.0 ± 0.0 39.0 ± 3.1 11.0 ± 2.9 27.0 ± 1.5 30.0 ± 1.0 2.0 21.0 ± 0.6 10.0 ± 0.6 15.0 ± 0.6 7.0 ± 0.0 52.0 ± 4.5 31.0 ± 3.2 43.0 ± 3.6 56.0 ± 1.7 4.0 40.0 ± 2.5 22.0 ± 1.2 30.0 ± 2.3 16.0 ± 0.6 69.0 ± 5.3 58.0 ± 3.5 55.0 ± 4.4 72.0 ± 1.2 8.0 72.0 ± 5.0 57.0 ± 7.4 57.0 ± 2.0 39.0 ± 1.0 85.0 ± 2.6 73.0 ± 2.6 67 ± 5.5 78.0 ± 0.6 12.0 95.0 ± 2.9 77.0 ± 5.3 77.0 ± 2.1 62.0 ± 3.6 88.0 ± 1.0 79.0 ± 2.1 83 ± 3.6 82.0 ± 0.0 - Formulations V, VI, and VII, which are modifications of Formulation IV of Example 2, include the following components as shown in Table 6 below.
TABLE 6 Formulation V Formulation VI Formulation VII Component mg/tablet % mg/tablet % mg/tablet % Anagrelide HCl, Monohydrate* 0.63 0.315 1.26 0.630 1.88 0.940 Polyethylene Oxide, 60 Mesh, NF 40.00 20.000 40.00 20.000 40.00 20.000 (Polyox ™ WSR N80) Dibasic Calcium Phosphate, Anhydrous, 39.21 19.605 37.18 18.590 38.56 19.280 USP (Fujicalin SG) Silicified High Density Microcrystalline 80.00 40.000 80.00 40.000 80.00 40.000 Cellulose (Prosolv HD 90), USP Methacrylic Acid Copolymer, NF 20.00 10.000 20.00 10.000 20.00 10.000 (Eudragit L 100-55) Glyceryl Behenate, NF 17.56 8.780 17.56 8.780 17.56 8.780 (Compritol 888 ATO) Magnesium Stearate Powder, NF 2.00 1.000 2.00 1.000 2.00 1.00 (Non-Bovine) Green PB-1763 0.60 0.300 — — — — Purple PB-1855 — — 2.00 1.000 — — Total 200.0 100.0 200.0 100.0 200.0 100.0 - Formulations V, VI, and VII were prepared and processed into tablets according to the following procedure:
- Blending
- 1. Weigh all the ingredients (Prosolv HD90 is divided into 3 portions).
- 2. Place the ingredients in the order listed below into the V-blender equipped with an intensifier bar:
- a. Prosolv
HD90 portion # 1 - b. Anagrelide HCl Monohydrate
- c. Green PB-1763 for Formulation V; Purple PB-1855 for Formulation VI strength; no color for Formulation VII
- d. Prosolv
HD90 portion # 2 - 3. Blend for 4 minutes in a V-blender with the intensifier bar off. Turn the intensifier bar on and blend for 2 minutes. Turn the intensifier bar off and blend for 4 minutes.
- 4. Pass the blend through a 30-mesh screen using a Comil at the low speed setting.
- 5. Pass Prosolv
HD90 portion # 3 through the same Comil using the 30-mesh screen and low speed. - 6. Place the ingredients into the larger V-blender equipped with an intensifier bar in the following order:
- a. Milled Prosolv HD90 from
Step 5 - b. Polyox WSR N80, 60 mesh
- c. Milled blend from
Step 4 - d. Eudragit L100-55
- e. Fujicalin SG
- 7. Blend these ingredients for 4 minutes with intensifier bar off. Turn the intensifier bar on and blend for 2 minutes. Turn the intensifier bar off, add Compritol 888 ATO and blend for 4 minutes.
- 8. Discharge this blend from the V-blender into a suitable container.
- 9. Pass Magnesium Stearate through a 30-mesh screen and collect it in a polyethylene bag.
- 10. Pass the blend from
step 8 through a 30-mesh screen using a Comil at the low speed setting and collect it in a polyethylene bag. - 11. Transfer the milled blend from
step 10 and the Magnesium Stearate fromstep 9 into the V-blender used instep 7 and mix for 5 minutes with the intensifier bar off. - 12. Discharge the blend from
step 11 into a polyethylene bag. - Tableting
- 1. Load the blend into the tablet press hopper.
- 2. Adjust the tablet weight to 200 mg and the appropriate tablet hardness.
- 3. Compress the blend into tablets using caplet-shaped tooling.
- 4. Take tablet samples as required by departmental SOPs to ensure product quality and to complete any process protocols of the tableting process.
- 5. Run tablets through an appropriate deduster.
- 6. Collect compressed tablets in a suitable container double lined with clean polyethylene bags.
-
Formulations TABLE 7 Amount, wt % Formulation Formulation Formulation Component 1 2 3 Anagrelide HCl, Monohydrate 0.61 0.61 0.61 Polyethylene Oxide 15.00 — 25.00 (Polyox ™ WSR 301) Polyethylene Oxide, 60 Mesh, — 20.00 — NF (Polyox ™ WSR N80) Dibasic Calcium Phosphate, 30.61 20.61 30.61 Anhydrous, USP (Fujicalin SG) Silicified High Density 30.00 40.00 15.00 Microcrystalline Cellulose (Prosolv HD 90), USP Methacrylic Acid Copolymer 10.00 10.00 15.00 (Eudragit L 100-55) Fumaric Acid 5.00 — 5.00 Glyceryl Behenate, NF 8.78 8.78 8.78 (Compritol 888 ATO) Total 100.0 100.0 100.0 - The purpose of this example was to assess the bioavailability of three anagrelide HCl extended release tablet
formulationsFormulation 1Formulation 2Formulation 3, compared to an immediate release anagrelide HCl formulation (Agrylin®, Lot No. RPA 0002A), following a 1 mg dose, and to determine the safety and tolerability of the extended release formulations in healthy volunteers. - The extent of absorption of each drug (AUCo-t) the maximum concentration of drug in plasma (Cmax), and the time of the maximum concentration (Tmax) were evaluated.
- The mean plasma concentrations for anagrelide following administration of a single 1 mg dose of Agrylin®, or the anagrelide HCl
extended release Formulations - The corresponding pharmacokinetic parameters for each formulation are given in Table 8 below.
TABLE 8 Mean Pharmacokinetic Parameters for Anagrelide Twidth AUC0-inf AUC0-t Cmax Tmax ♭Cmax Treatment (ng · hr/mL) (ng · hr/mL) (ng/mL) (hr) (hr) Formulation 19.24* 8.47* 1.15* 3.41* 5.06 Formulation 210.32* 9.10* 1.01* 3.17* 5.99 Formulation 39.41* 8.48* 1.17* 3.46* 4.30 Agrylin ® 14.89 14.46 5.67 1.25 2.17 Bioequivalence Formulation 1: 0.61 0.58 0.21 Ratio of test-to-ref. 90% CI 0.49-0.76 0.46-0.73 0.17-0.27 Formulation 2: 0.59 0.53 0.17 Ratio of test-to-ref. 90% CI 0.47-0.74 0.42-0.67 0.14-0.22 Formulation 3: 0.66 0.64 0.25 Ratio of test-to-ref. 90% CI 0.52 0.50-0.81 0.20-0.32 - All three experimental formulations exhibited extended release characteristics for drug delivery. The extent of absorption of anagrelide from the experimental formulations relative to immediate-release Agrylin® (ratio of test-to-reference) was 58%, 53% and 64% for the
Formulations - A measure of the extent of delay in release of active pharmaceutical ingredient of the experimental formulations was the time to reach maximum concentration (Tmax) values observed for anagrelide. The Tmax values were approximately 2 hours later than that observed for Agrylin®, demonstrating about a 2.6-fold delay in time to reach Cmax for the three extended release formulations compared with the immediate-release Agrylin®. Furthermore, the length of time at which the anagrelide plasma concentration remained above ½Cmax (Twidth ½Cmax) was approximately two- to three-fold greater for the extended release formulations than the immediate release formulation, demonstrating good extended release characteristics.
- No serious adverse events were reported. One subject discontinued due to an adverse event (head cold) considered not related to study drug. There were a total of 46 adverse events (AEs) experienced by eleven (11) subjects. The most frequently reported events (>5%), included asthenia, headache, somnolence, and dizziness, and were not unexpected. These events have been reported frequently by the target patient population at large receiving Agrylin® for the treatment of thrombocythemia secondary to all myeloproliferative disorders. Treatment emergent AEs are summarized in Table 9.
TABLE 9 Treatment Emergent AEs Preferred Term (Costart) Count % (n = 12) Asthenia 12 26.1 Headache 9 19.6 Somnolence 6 13.0 Dizziness 5 10.9 Tachycardia 2 4.3 Infection 2 4.3 Nausea 2 4.3 Vomit 2 4.3 Pain Abd 1 2.2 Palpitations 1 2.2 Pain 1 2.2 Hem 1 2.2 Voice alteration 1 2.2 Thirst 1 2.2 Total 46 100.0 - The data would indicate that adverse events (AEs) observed in subjects following dosage with the extended release formulation were not as prevalent as AEs observed following the immediate release formulation (Agrylin®). More than 50% of the reported AEs were observed following Agrylin® administration. The number of adverse events following administration of the new extended release formulations were 8/46 (17%) for
Formulation Formulation Formulation 3 compared to 25/46 (54%) for the marketed Agrylin®. The incidence of subjects reporting adverse events for the new extended-release formulations (4/12 (33%), 6/12 (50%), and 2/12 (17%) forFormulations TABLE 10 Treatment Emergent Adverse Events per Treatment Group Preferred No. % Term Subjects Subjects No. AEs Drug Treatment (Costart) Reporting Reporting Reported Formulation 1Asthenia 3 25.0 3 (n = 12) Nausea 1 8.3 1 Pain 1 8.3 1 Somnolence 1 8.3 1 Thirst 1 8.3 1 Vomit 1 8.3 1 Formulation 2Asthenia 3 25.0 3 (n = 12) Dizziness 2 16.7 2 Headache 2 16.7 2 Somnolence 1 8.3 1 Hem 1 8.3 1 Formulation 3Asthenia 1 9.3 1 (n = 11) Headache 1 9.3 1 Infect 1 9.3 1 Voice 1 9.3 1 alteration Agrylin ® Headache 6 50.0 6 (n = 12) Asthenia 5 41.7 5 Somnolence 3 25.0 4 Dizziness 3 25.0 3 Tacchycardia 2 16.7 2 Nausea 1 8.3 1 Pain 1 8.3 1 Abdominal Infect 1 8.3 1 Vomit 1 8.3 1 Palpitations 1 8.3 1 Total (n = 12) 46 - With respect to clinical laboratory and physical examination findings, statistically significant (p<0.01) increases in pulse compared with baseline were observed with Agrylin® at 2, 4, and 24 hours post dose. Significant increases were observed at 24 hours post dose for
Formulations - It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.
Claims (73)
1. A pharmaceutical composition, comprising:
(a) at least one pharmaceutically active agent that is pH dependent:
(b) at least one non-pH dependent sustained release agent; and
(c) at least one pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5.
2. The composition of claim 1 wherein said at least one pH dependent agent is at least one polymer that swells at a pH in excess of 5.5.
3. The composition of claim 1 wherein said at least one pH dependent agent is at least one enteric agent.
4. The composition of claim 1 wherein said at least one pH dependent agent is at least one agent that increases the solubility of said at least one pharmaceutically active agent at a pH of greater than 5.5.
5. The composition of claim 1 wherein said at least one pharmaceutically active agent is selected from the group consisting of guanfacine, anagrelide, guanethidine monosulfate, quanadrel sulfate, resirpine, propanolol, metoprolol, atenolol, timolol, erythromycin, clonidine, chlorpheniramine, bromopheniramine, diltiazem, and scopolamine.
6. The composition of claim 5 wherein said at least one pharmaceutically active agent guanfacine.
7. The composition of claim 5 wherein said at least one pharmaceutically active agent guanfacine hydrochloride.
8. The composition of claim 5 wherein said at least one pharmaceutically active agent is anagrelide.
9. The composition of claim 5 wherein said at least one pharmaceutically active agent is anagrelide hydrochloride.
10. The composition of claim 1 wherein said non-pH dependent sustained release agent is selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, trgacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
11. The composition of claim 2 wherein said at least one polymer that swells at a pH in excess of 5.5 is selected from the group consisting of acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.
12. The composition of claim 3 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
13. The composition of claim 4 wherein said at least one agent that increase the solubility of said at least one pharmaceutically active agent at a pH greater than 5.5 is at least one organic acid.
14. The composition of claim 13 wherein said at least one organic acid is selected from the group consisting of citric acid, fumaric acid, tartaric acid, adipic acid, glucono delta-lactone, and malic acid.
15. The composition of claim I wherein said pH-dependent agent that increases the rate of release of the at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5 is an agent that maintains an acidic microenvironment in the composition.
16. The composition of claim 14 wherein said organic acid is fumaric acid.
17. The composition of claim 1 and further comprising a binding agent.
18. The composition of claim 17 wherein said binding agent is selected from the group consisting of polyvinyl pyrrolidone, starch, methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, sucrose solution, dextrose solution, acacia, tragacanth, and locust bean gum.
19. The composition of claim 18 wherein said binder is hydroxypropyl methylcellulose.
20. The composition of claim 1 wherein said pharmaceutically active agent is present in the composition in an amount of from about 0.1 wt. % to about 70 wt. %.
21. The composition of claim 20 wherein said pharmaceutically active agent is present in the composition in an amount of from about 1 wt. % to about 40 wt. %.
22. The composition of claim 1 wherein said non-pH-dependent sustained release agent is present in the composition in an amount of from about 5 wt. % to about 50 wt. %.
23. The composition of claim 22 wherein said non-pH-dependent sustained release agent is present in the composition in an amount of from about 10 wt. % to about 30 wt. %.
24. The composition of claim 1 wherein said at least one pH-dependent agent is present in the composition in an amount of from about 0.5 wt. % to about 40 wt. %.
25. The composition of claim 24 wherein said at least one pH-dependent agent is present in the composition in an amount of from about 1 wt. % to about 20 wt. %.
26. The composition of claim 10 wherein said non-pH-dependent sustained release agent is ethyl cellulose.
27. The composition of claim 10 wherein said non-pH-dependent sustained release agent is hydroxypropyl methylcellulose.
28. The composition of claim 10 wherein said non-pH-dependent sustained release agent is an acrylate/methacrylate copolymer.
29. The composition of claim 10 wherein said non-pH-dependent sustained release agent is polyethylene oxide.
30. The composition of claim 11 wherein said at least one polymer that swells at a pH in excess of 5.5 is sodium alginate.
31. The composition of claim 12 wherein said at least one enteric agent is a methacrylic acid copolymer.
32. The composition of claim 1 wherein said composition is in the form of a tablet.
33. The composition of claim 6 or 7 wherein said non-pH-dependent sustained release agent is selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
34. The composition of claim 6 or 7 wherein said at least one pH-dependent agent is at least one polymer that swells at a pH in excess of 5.5.
35. The composition of claim 34 wherein said at least one polymer that swells at a pH in excess of 5.5 is selected from the group consisting of acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.
36. The composition of claim 6 or 7 wherein said at least one pH-dependent agent is at least one enteric agent.
37. The composition of claim 36 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
38. The composition of claim 8 or 9 wherein said non-pH-dependent sustained release agent is selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methylcellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol.
39. The composition of claim 38 wherein said non-pH-dependent sustained release agent is polyethylene oxide.
40. The composition of claim 8 or 9 wherein said at least one pH-dependent agent is at least one enteric agent.
41. The composition of claim 40 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.
42. The composition of claim 41 wherein said at least one enteric agent is a methacrylic acid copolymer.
43. The composition of claim 8 or 9 and further comprising a bulking agent.
44. The composition of claim 43 wherein said bulking agent is dibasic calcium phosphate.
45. The composition of claim 43 wherein said bulking agent is microcrystalline cellulose.
46. The composition of claim 8 or 9 and further comprising a lubricant.
47. The composition of claim 46 wherein said lubricant is glyceryl behenate.
48. The composition of claim 46 wherein said lubricant is magnesium stearate.
49. A pharmaceutical composition, comprising:
(a) anagrelide;
(b) polyethylene oxide;
(c) dibasic calcium phosphate;
(d) microcrystalline cellulose;
(e) a methacrylic acid copolymer;
(f) glyceryl behenate; and
(g) magnesium stearate.
50. A pharmaceutical composition, comprising:
(h) Anagrelide hydrochloride;
(i) polyethylene oxide;
(j) dibasic calcium phosphate;
(k) microcrystalline cellulose;
(l) a methacrylic acid copolymer;
(m) glyceryl behenate; and
(n) magnesium stearate.
51. A method of treating a myeloproliferative blood disorder in a patient, comprising: administering to said patient the composition of anyone of claims 8 to 50 in an amount effective to treat said myeloproliferative blood disorder in said patient.
52. The method of claim 51 wherein said myeloproliferative blood disorder is essential thrombocythemia.
53. The method of claim 51 wherein said myeloproliferative blood disorder is chronic myelogenous leukemia.
54. The method of claim 51 wherein said myeloproliferative blood disorder is polycythemia vera.
55. The method of claim 51 wherein said myeloproliferative blood disorder is agnogenic myeloid metaplasia.
56. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.01 mg to about 15 mg.
57. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.1 mg to about 10 mg.
58. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.1 mg to about 5 mg.
59. The method of claim 51 wherein the amount of the active ingredient anagrelide is about 0.5mg to about 2 mg.
60. A pharmaceutical composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.
61. The pharmaceutical composition of claim 60 wherein said side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Vomit, Infect or Palpitations.
62. The pharmaceutical composition of claim 61 wherein said side effects are chosen from Headache and Asthenia.
63. The pharmaceutical composition of claim 61 wherein said side effect is Headache.
64. The pharmaceutical composition of claim 61 wherein said side effect is Asthenia.
65. A method of reducing the likelihood of side effects associated with the administration of anagrelide, comprising administering to a patient a therapeutically effective amount of a composition as defined in anyone of claims 8 to 50 .
66. The method of claim 65 wherein said side effects are chosen from Headache, Asthenia, Somnolence, Dizziness, Tacchycardia, Nausea, Pain Abdominal, Vomit, Infect, or Palpitations.
67. The method of claim 65 wherein said side effects are chosen from Headache and Asthenia.
68. The method of claim 65 wherein said side effect is Headache.
69. The method of claim 65 wherein said side effect is Asthenia
70. A pharmaceutical composition, comprising:
(a) guanfacine;
(b) Hydroxypropyl Methylcellulose
(c) Ammonio Methacrylate Copolymer
(d) microcrystalline cellulose;
(e) a methacrylic acid copolymer;
(f) glyceryl behenate; and
(g) Fumaric Acid,
(h) Lactose Monohydrate
(i) Povidone; and
(j) Crospovidone Granulated Blend.
71. A pharmaceutical composition comprising:
(a) Guanfacine hydrochloride;
(b) Hydroxypropyl Methylcellulose
(c) Ammonio Methacrylate Copolymer
(d) microcrystalline cellulose;
(e) a methacrylic acid copolymer;
(f) glyceryl behenate; and
(g) Fumaric Acid,
(h) Lactose Monohydrate
(i) Povidone; and
(j) Crospovidone Granulated Blend.
72. A method of treating an attention deficit disorder or attention deficit with hyperactivity disorder in a patient, comprising administering to said patient the composition of claim 6 or 7 in an amount effective to treat said attention deficit disorder or attention deficit with hyperactivity disorder in said patient.
73. A method of reducing the likelihood of side effects associated with the administration of guanfacine, comprising administering to a patient a therapeutically effective amount of the composition of claim 6 or 7
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/451,271 US20040062800A1 (en) | 2000-12-20 | 2001-12-20 | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09741548 | 2000-12-20 | ||
US09/741,548 US6287599B1 (en) | 2000-12-20 | 2000-12-20 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
PCT/US2001/050773 WO2002058676A1 (en) | 2000-12-20 | 2001-12-20 | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
US10/451,271 US20040062800A1 (en) | 2000-12-20 | 2001-12-20 | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040062800A1 true US20040062800A1 (en) | 2004-04-01 |
Family
ID=24981155
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/741,548 Expired - Lifetime US6287599B1 (en) | 2000-12-20 | 2000-12-20 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US10/451,271 Abandoned US20040062800A1 (en) | 2000-12-20 | 2001-12-20 | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/741,548 Expired - Lifetime US6287599B1 (en) | 2000-12-20 | 2000-12-20 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Country Status (10)
Country | Link |
---|---|
US (2) | US6287599B1 (en) |
EP (1) | EP1351668B1 (en) |
JP (1) | JP4340840B2 (en) |
AU (1) | AU2002249881B2 (en) |
CA (1) | CA2432178C (en) |
CY (1) | CY1116023T1 (en) |
DK (1) | DK1351668T3 (en) |
ES (1) | ES2527854T3 (en) |
PT (1) | PT1351668E (en) |
WO (1) | WO2002058676A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040087486A1 (en) * | 1999-09-21 | 2004-05-06 | Hanson Stephen R. | Methods and compositions for treating platelet-related disorders |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
WO2007054976A2 (en) * | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20080213368A1 (en) * | 2004-12-27 | 2008-09-04 | Eisai R & D Management Co., Ltd. | Method for Stabilizing Anti-Dementia Drug |
US20090023778A1 (en) * | 2005-04-28 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Composition Containing Anti-Dementia Drug |
US20090087490A1 (en) * | 2007-06-08 | 2009-04-02 | Addrenex Pharmaceuticals, Inc. | Extended release formulation and method of treating adrenergic dysregulation |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US20090324710A1 (en) * | 2008-06-16 | 2009-12-31 | Glidden Paul F | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
AT10562U3 (en) * | 2008-12-05 | 2010-01-15 | Aop Orphan Pharmaceuticals Ag | A NEW COMPOSITION FOR TREATING AN ESSENCIAL THROMBOCYTEMIA |
US20100172991A1 (en) * | 2007-06-08 | 2010-07-08 | Henry Joseph Horacek | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation |
WO2011085466A1 (en) | 2010-01-18 | 2011-07-21 | Medizone International Inc. | Bio-terrorism counteraction using ozone and hydrogen peroxide |
WO2011117391A3 (en) * | 2010-03-25 | 2012-01-19 | Aop Orphan Pharmaceuticals Ag | Novel composition for treatment of essential thrombocythemia |
US8906420B2 (en) | 2009-01-09 | 2014-12-09 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
US9011912B2 (en) | 2010-10-07 | 2015-04-21 | Abon Pharmaceuticals, Llc | Extended-release oral dosage forms for poorly soluble amine drugs |
WO2017182852A1 (en) * | 2016-04-20 | 2017-10-26 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
US9962345B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Oral liquid compositions of guanfacine |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
US10285908B2 (en) | 2014-07-30 | 2019-05-14 | Sun Pharmaceutical Industries Ltd | Dual-chamber pack |
US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
US11504345B2 (en) | 2014-05-01 | 2022-11-22 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
AR035216A1 (en) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
AR034517A1 (en) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | PHARMACEUTICAL FORMULATION |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
WO2003039530A1 (en) * | 2001-11-07 | 2003-05-15 | Synthon B.V. | Tamsulosin tablets |
KR101016619B1 (en) * | 2001-11-13 | 2011-02-23 | 아스텔라스세이야쿠 가부시키가이샤 | Soluble drug extended release system |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
KR100540035B1 (en) * | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | Multi-stage oral drug controlled-release system |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
KR101002374B1 (en) * | 2002-02-26 | 2010-12-17 | 아스트라제네카 아베 | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
AU2003230805A1 (en) * | 2002-04-05 | 2003-10-27 | Penwest Pharmaceuticals Co. | Sustained release metoprolol formulations |
SE0201661D0 (en) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
WO2003105810A1 (en) * | 2002-06-14 | 2003-12-24 | Andrx Corporation | Pharmaceutical compositions for drugs having ph-dependentsolubility |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
BR0315731A (en) * | 2002-10-30 | 2005-09-06 | Pharmacia Corp | Extended-Release Oral Tablets and Methods for Manufacturing and Using Them |
US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
ATE339192T1 (en) * | 2003-05-14 | 2006-10-15 | Eurand Pharmaceuticals Ltd | CONTROLLED DRUG RELEASE COMPOSITION WITH IN VIVO MECHANICAL STRESS RESISTANCE |
US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
US7198653B2 (en) | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
US20050106253A1 (en) * | 2003-11-13 | 2005-05-19 | Platteeuw Johannes J. | Pharmaceutical pellets comprising tamsulosin |
CN101005830B (en) * | 2004-08-13 | 2010-09-29 | 贝林格尔·英格海姆国际有限公司 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
ES2409347T3 (en) | 2004-10-21 | 2013-06-26 | Aptalis Pharmatech, Inc. | Pharmaceutical compositions of masked flavor with gastro-soluble porogenic agents |
US8128952B2 (en) * | 2005-01-12 | 2012-03-06 | Clemson University Research Foundation | Ligand-mediated controlled drug delivery |
JP2008530131A (en) * | 2005-02-15 | 2008-08-07 | ジャズ、ファーマシューティカルズ、インコーポレイテッド | Dosage forms and methods for sustained release of substituted pyrazine compounds |
US20060204575A1 (en) * | 2005-03-11 | 2006-09-14 | Hengsheng Feng | Amphetamine formulations |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
EP1898886B1 (en) | 2005-07-01 | 2019-09-04 | Rubicon Research Pvt Ltd. | Novel sustained release dosage form |
DK1909766T3 (en) * | 2005-07-28 | 2016-04-04 | Shire Llc | PHARMACEUTICAL FORMULATIONS / FORMATIONS OF guanfacine SUITABLE FOR DAILY ADMINISTRATION IN SINGLE DOSE FORM |
US8778395B2 (en) * | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
BRPI0615135A2 (en) * | 2005-08-26 | 2016-09-13 | Bpsi Holdings Inc | drug compositions containing controlled release hypromellose matrices |
DK1931346T3 (en) | 2005-09-09 | 2012-10-22 | Angelini Labopharm Llc | Trazodone composition for once daily administration |
WO2007035874A1 (en) * | 2005-09-21 | 2007-03-29 | Bristol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
US20070092573A1 (en) * | 2005-10-24 | 2007-04-26 | Laxminarayan Joshi | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
US20070238942A1 (en) * | 2006-04-10 | 2007-10-11 | Esophamet Corp. | Apparatus and method for detecting gastroesophageal reflux disease (gerd) |
MX2008013675A (en) | 2006-04-26 | 2009-03-06 | Supernus Pharmaceuticals Inc | Controlled released preparations of oxcarbazepine having sigmoidal release profile. |
KR100780479B1 (en) | 2006-05-08 | 2007-11-28 | 윈셋파마 주식회사 | Oral drug comprising Ibudilast and manufacturing method |
WO2007131804A1 (en) | 2006-05-17 | 2007-11-22 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
US20070281011A1 (en) * | 2006-05-30 | 2007-12-06 | Elan Pharma International Ltd. | Nanoparticulate posaconazole formulations |
US9138414B1 (en) | 2006-09-15 | 2015-09-22 | Delavau Llc | Calcium supplement having enhanced absorption |
TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
TW200900033A (en) * | 2007-06-21 | 2009-01-01 | Wen-Qing Li | Automatic brewing machine |
US20090022789A1 (en) * | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
ES2402342T3 (en) | 2008-08-01 | 2013-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Quetiapine Composition |
US20100159001A1 (en) | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
US8465770B2 (en) * | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
CN102438617A (en) | 2009-03-27 | 2012-05-02 | 杏林制药株式会社 | Matrix-type sustained release preparation containing basic additive |
EP2506836B1 (en) | 2009-12-02 | 2018-02-14 | Adare Pharmaceuticals S.R.L. | Fexofenadine microcapsules and compositions containing them |
US20110217373A1 (en) * | 2010-01-29 | 2011-09-08 | Kumaravel Vivek | Extended release pharmaceutical compositions of guanfacine hydrochloride |
EP2540294B1 (en) | 2010-02-22 | 2016-08-03 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
JP5749247B2 (en) | 2010-02-22 | 2015-07-15 | 第一三共株式会社 | Oral sustained-release solid preparation |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
JP2013526601A (en) * | 2010-05-24 | 2013-06-24 | ルピン・リミテッド | Sustained release formulation of pramipexole |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
MX2021000431A (en) | 2011-03-23 | 2022-10-28 | Ironshore Pharmaceuticals & Dev Inc | Methods and compositions for treatment of attention deficit disorder. |
WO2013147135A1 (en) * | 2012-03-30 | 2013-10-03 | アステラス製薬株式会社 | Controlled-release pharmaceutical composition |
ES2706994T3 (en) | 2012-09-03 | 2019-04-02 | Daiichi Sankyo Co Ltd | Orally extended-release pharmaceutical composition containing hydromorphone hydrochloride |
AU2013318182C1 (en) | 2012-09-18 | 2022-01-20 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
US20160022591A1 (en) * | 2013-03-15 | 2016-01-28 | Mylan Inc. | Extended release pharmaceutical solid dosage formulations |
US20140309270A1 (en) | 2013-04-11 | 2014-10-16 | Richard Louis Price | Diagnosis and treatment of a form of autistic spectrum disorder |
US20170348417A1 (en) | 2013-04-11 | 2017-12-07 | Richard Louis Price | Treatment of attention deficit disorders and associated symptoms |
US9603812B2 (en) | 2013-04-11 | 2017-03-28 | Richard Louis Price | Treatment of autistic spectrum disorder |
US10098848B2 (en) | 2013-04-11 | 2018-10-16 | Richard Louis Price | Inositol-containing comestible units and methods of treatment using the same |
US9211284B2 (en) | 2013-04-11 | 2015-12-15 | Richard Louis Price | Diagnosis and treatment of P.R.I.C.E. syndrome |
EP2796133A1 (en) | 2013-04-26 | 2014-10-29 | Salmon Pharma GmbH | Sustained release guanfacine HCl formulation |
EP3076970A4 (en) | 2013-12-03 | 2017-07-26 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
CN103784413A (en) * | 2014-02-27 | 2014-05-14 | 中国药科大学 | Atenolol pH independent sustained-release tablets and preparation method thereof |
PL2915526T3 (en) | 2014-03-07 | 2021-12-20 | Galenicum Health S.L.U. | Pharmaceutical compositions comprising anagrelide |
KR102335744B1 (en) | 2015-03-06 | 2021-12-07 | 오스펙스 파마슈티칼스, 인코포레이티드 | Methods for treating abnormal involuntary movement disorders |
KR20200118507A (en) | 2016-02-29 | 2020-10-15 | 에프. 호프만-라 로슈 아게 | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
KR102078462B1 (en) * | 2018-07-24 | 2020-02-17 | 주식회사 디네이쳐 | Composition for improving vagina environment and improving agent having the same |
PL3976000T3 (en) * | 2019-04-05 | 2023-12-04 | Gedea Biotech Ab | Vaginal tablet formulation |
JP7149449B2 (en) * | 2020-07-02 | 2022-10-06 | ARTham Therapeutics株式会社 | Oral pharmaceutical composition and manufacturing method thereof |
EP4292587A1 (en) | 2022-06-15 | 2023-12-20 | Sawai Pharmaceutical Co., Ltd. | Guanfacine hydrochloride containing pharmaceutical preparation |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4404226A (en) * | 1981-07-09 | 1983-09-13 | Sandoz Ltd. | Use of guanfacine in treating schizophrenia |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5246714A (en) * | 1985-10-11 | 1993-09-21 | Aktiebolaget Hassle | Drug preparation |
US5378474A (en) * | 1989-01-06 | 1995-01-03 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5605911A (en) * | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07116044B2 (en) * | 1987-10-16 | 1995-12-13 | エラン コーポレーション ピー エル シー | Diltiazem formulations with controlled absorption and methods for their production and use |
KR900701255A (en) * | 1988-11-30 | 1990-12-01 | 스테이너 브이.캔스타드 | Sustained Release Diltiazem Formulations |
US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
WO1999020223A2 (en) * | 1997-10-20 | 1999-04-29 | Novo Nordisk A/S | Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive |
US6337091B1 (en) * | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
PE20001396A1 (en) * | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | DELAYED MEDICINAL FORMULATIONS CONTAINING A COMBINATION OF AN OPIOID OR A PHYSIOLOGICALLY TOLERABLE SALT OF THE SAME, AN O-AGONIST |
-
2000
- 2000-12-20 US US09/741,548 patent/US6287599B1/en not_active Expired - Lifetime
-
2001
- 2001-12-20 WO PCT/US2001/050773 patent/WO2002058676A1/en active Application Filing
- 2001-12-20 AU AU2002249881A patent/AU2002249881B2/en not_active Expired
- 2001-12-20 JP JP2002559010A patent/JP4340840B2/en not_active Expired - Lifetime
- 2001-12-20 EP EP01998126.5A patent/EP1351668B1/en not_active Expired - Lifetime
- 2001-12-20 ES ES01998126.5T patent/ES2527854T3/en not_active Expired - Lifetime
- 2001-12-20 DK DK01998126.5T patent/DK1351668T3/en active
- 2001-12-20 CA CA2432178A patent/CA2432178C/en not_active Expired - Lifetime
- 2001-12-20 PT PT1998126T patent/PT1351668E/en unknown
- 2001-12-20 US US10/451,271 patent/US20040062800A1/en not_active Abandoned
-
2014
- 2014-12-29 CY CY20141101090T patent/CY1116023T1/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4404226A (en) * | 1981-07-09 | 1983-09-13 | Sandoz Ltd. | Use of guanfacine in treating schizophrenia |
US5246714A (en) * | 1985-10-11 | 1993-09-21 | Aktiebolaget Hassle | Drug preparation |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US5378474A (en) * | 1989-01-06 | 1995-01-03 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5605911A (en) * | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100008913A1 (en) * | 1999-09-21 | 2010-01-14 | Hanson Stephen R | Methods and compositions for treating platelet-related disorders |
US20040087486A1 (en) * | 1999-09-21 | 2004-05-06 | Hanson Stephen R. | Methods and compositions for treating platelet-related disorders |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20100152164A1 (en) * | 2004-12-27 | 2010-06-17 | Eisai R&D Management Co., Ltd. | Method For Stabilizing Anti-Dementia Drug |
US20080213368A1 (en) * | 2004-12-27 | 2008-09-04 | Eisai R & D Management Co., Ltd. | Method for Stabilizing Anti-Dementia Drug |
US8507527B2 (en) | 2004-12-27 | 2013-08-13 | Eisai R & D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20090023778A1 (en) * | 2005-04-28 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Composition Containing Anti-Dementia Drug |
WO2007054976A2 (en) * | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
WO2007054976A3 (en) * | 2005-11-08 | 2007-08-09 | Panacea Biotec Ltd | Lipid based controlled release pharmaceutical composition |
US7884122B2 (en) | 2007-06-08 | 2011-02-08 | Shionogi Pharma, Inc. | Extended release formulation and method of treating adrenergic dysregulation |
US20100172991A1 (en) * | 2007-06-08 | 2010-07-08 | Henry Joseph Horacek | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation |
US20100209510A1 (en) * | 2007-06-08 | 2010-08-19 | Henry Joseph Horacek | Extended Release Formulation and Method of Treating Adrenergic Dysregulation |
US20090087490A1 (en) * | 2007-06-08 | 2009-04-02 | Addrenex Pharmaceuticals, Inc. | Extended release formulation and method of treating adrenergic dysregulation |
US20090324710A1 (en) * | 2008-06-16 | 2009-12-31 | Glidden Paul F | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
US9381198B2 (en) | 2008-06-16 | 2016-07-05 | Biovascular, Inc. | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
US9040483B2 (en) | 2008-06-16 | 2015-05-26 | Biovascular, Inc. | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
AT10562U3 (en) * | 2008-12-05 | 2010-01-15 | Aop Orphan Pharmaceuticals Ag | A NEW COMPOSITION FOR TREATING AN ESSENCIAL THROMBOCYTEMIA |
US11173123B2 (en) | 2009-01-09 | 2021-11-16 | Biogen Swiss Manufacturing Gmbh | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
US8906420B2 (en) | 2009-01-09 | 2014-12-09 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
WO2011085466A1 (en) | 2010-01-18 | 2011-07-21 | Medizone International Inc. | Bio-terrorism counteraction using ozone and hydrogen peroxide |
AU2011231557B2 (en) * | 2010-03-25 | 2016-05-26 | Aop Orphan Pharmaceuticals Ag | Novel composition for treatment of essential thrombocythemia |
EA027576B1 (en) * | 2010-03-25 | 2017-08-31 | Аоп Орфан Фармацойтикальс Аг | Novel composition for treatment of essential thrombocythemia |
WO2011117391A3 (en) * | 2010-03-25 | 2012-01-19 | Aop Orphan Pharmaceuticals Ag | Novel composition for treatment of essential thrombocythemia |
US9011912B2 (en) | 2010-10-07 | 2015-04-21 | Abon Pharmaceuticals, Llc | Extended-release oral dosage forms for poorly soluble amine drugs |
US9962345B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Oral liquid compositions of guanfacine |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
US11504345B2 (en) | 2014-05-01 | 2022-11-22 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
US11523996B2 (en) | 2014-05-01 | 2022-12-13 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
US10285908B2 (en) | 2014-07-30 | 2019-05-14 | Sun Pharmaceutical Industries Ltd | Dual-chamber pack |
WO2017182852A1 (en) * | 2016-04-20 | 2017-10-26 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
EP1351668A4 (en) | 2007-01-31 |
US6287599B1 (en) | 2001-09-11 |
PT1351668E (en) | 2015-01-13 |
WO2002058676A1 (en) | 2002-08-01 |
EP1351668A1 (en) | 2003-10-15 |
JP2004518676A (en) | 2004-06-24 |
CA2432178A1 (en) | 2002-08-01 |
CA2432178C (en) | 2010-04-20 |
EP1351668B1 (en) | 2014-10-15 |
ES2527854T3 (en) | 2015-01-30 |
AU2002249881B2 (en) | 2006-12-21 |
JP4340840B2 (en) | 2009-10-07 |
CY1116023T1 (en) | 2017-01-25 |
DK1351668T3 (en) | 2015-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6811794B2 (en) | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | |
CA2432178C (en) | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles | |
AU2002249881A1 (en) | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | |
CN106943355B (en) | Pharmaceutical composition | |
EP2397122B1 (en) | Formulations of neramexane dosage forms | |
JPH061716A (en) | Medical prescription having long-term releasability of active ingredient | |
CA2387621A1 (en) | Extended release formulations of erythromycin derivatives | |
CN110876750A (en) | Sustained-release composition containing ticagrelor or pharmaceutically acceptable salt thereof | |
KR20100020447A (en) | Extended release formulation of nevirapine | |
AU2005256653B2 (en) | Oral sustained release formulation of tedisamil with gastric retention properties | |
CA2616845A1 (en) | Modified release tablet formulations with enhanced mechanical properties | |
WO2020138791A2 (en) | Sustained-release preparation comprising tofacitinib or pharmaceutically acceptable salt thereof and manufacturing method therefor | |
EP2391353B1 (en) | Pharmaceutical compositions of trimetazidine | |
AU2003253198A1 (en) | Bicifadine formulation | |
WO2009043914A1 (en) | Multi particulate matrix system containing galantamine | |
EP3335702A1 (en) | Pharmaceutical compositions comprising omarigliptin | |
US20050142193A1 (en) | Galantamine formulations | |
KR20190120092A (en) | Oral Tablet Formulation of Lenalidomide with various doses | |
US20070104782A1 (en) | Modified release tablet formulations with enhanced mechanical properties | |
EP2044933A1 (en) | Multi particulate matrix system containing galantamine | |
EP3335703A1 (en) | Pharmaceutical composition comprising omarigliptin | |
AU2006335344A1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
US20230172863A1 (en) | Modified-release dosage forms of ruxolitinib | |
EP4251154A1 (en) | Sustained release formulation compositions comprising propiverine | |
NZ760868B2 (en) | A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUPERNUS PHARMACEUTICALS, INC, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHIRE LABORATORIES, INC;REEL/FRAME:017596/0304 Effective date: 20060425 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |